Related Experiment Video
Updated: Aug 26, 2025
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Levosimendan: mechanistic insight and its diverse future aspects in cardiac care
Md Sayeed Akhtar1, Md Quamrul Hassan2, Aisha Siddiqui3
1College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Insights
Levosimendan (LEVO) is a novel inodilator that enhances cardiac contractility and vasodilation. This review explores its unique pharmacology and clinical benefits as an emerging therapeutic alternative for acute decompensated heart failure (HF) and cardiac surgery patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute decompensated heart failure with reduced ejection fraction (HFrEF) often requires inotropic support.
- Traditional inotropic agents have limitations, including life-threatening arrhythmias and tolerance.
- Calcium sensitizers represent an emerging therapeutic alternative.
Purpose of the Study:
- To review the basic pharmacology of Levosimendan (LEVO).
- To explore the potential clinical aspects of LEVO in cardiac surgery and other heart failure alterations.
- To identify research gaps and guide future investigations.
Main Methods:
- Literature review of existing evidence on Levosimendan.
- Compilation of pharmacological data and clinical trial outcomes.
- Analysis of Levosimendan's efficacy in various cardiac conditions.
Main Results:
- Levosimendan (LEVO) acts as an inodilator, increasing cardiomyocyte sensitivity to calcium ions.
- LEVO demonstrates efficacy in a wide range of cardiac alterations, particularly in cardiac surgery.
- It offers improved cardiac mechanical efficacy and reduced congestion compared to classical inotropes, especially in hypotensive acute HF patients.
Conclusions:
- Levosimendan (LEVO) presents a unique pharmacological profile beneficial for heart failure management.
- Its application in cardiac surgery and acute heart failure warrants further research.
- This review provides a foundation for future research into Levosimendan's therapeutic potential.
Abstract:
Inotropic agents are generally recommended to use in patients with acute decompensated heart failure (HF) with reduced ejection fraction (HFrEF) concurrent to end-organ dysfunction. However, due to certain pharmacological limitations like developing life threatening arrhythmia and tolerance, cannot be employed as much as needed. Meanwhile, Calcium ion (Ca2+) sensitisers exhibits their inotropic action by increasing the sensitivity of the cardiomyocyte to intracellular Ca2+ ion and have been reported as emerging therapeutic alternative in HF cases. Levosimendan (LEVO) is an inodilator and with its unique pharmacology justifying its use in a wide range of cardiac alterations in HF particularly in undergoing cardiac surgery. It is also reported to be better than classical inotropes in maintaining cardiac mechanical efficacy and reducing congestion in acute HF with hypotension. This review paper was designed to compile various evidence about basic pharmacology and potential clinical aspects of LEVO in cardiac surgery and other HF associated alterations. This will benefit directly to the researcher in initiating research and to fill the gaps in the area of thrust.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:30Heart Failure V: Medical Management
01:29Heart Failure II: Pathophysiology
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:29Cardiomyopathy V: Interprofessional Care
01:29Pathophysiology of Cardiac Performance